A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: Results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG

Annals of Oncology

Volumn 25, Issue 3, 2014, Pages 599-605

  Smorenburg, C H ^a   De Groot, S M ^b   Van Leeuwen Stok, A E ^c   Hamaker, M E ^d   Wymenga, A N ^e   De graaf, H ^f   De Jongh, F E ^g   Braun, J J ^h   Los, M ⁱ   Maartense, E ^j   Van Tinteren, H ^k   Nortier, J W R ^l   Seynaeve, C ^m  

^a Location Alkmaar   (Netherlands)

^b Integraal Kankercentrum Amsterdam   (Netherlands)

^c Dutch Breast Cancer Trialists' Group BOOG   (Netherlands)

^d DEPARTMENT OF SURGERY   (Netherlands)

^e MEDISCH SPECTRUM TWENTE   (Netherlands)

^f MEDICAL CENTER LEEUWARDEN   (Netherlands)

^g IKAZIA HOSPITAL   (Netherlands)

^h Vlietland Hospital   (Netherlands)

ⁱ ST ANTONIUS HOSPITAL   (Netherlands)

^j REINIER DE GRAAF HOSPITAL   (Netherlands)

^k NETHERLANDS CANCER INSTITUTE   (Netherlands)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Capecitabine; Elderly; Geriatric; Metastatic breast cancer; Pegylated liposomal doxorubicin; Phase III

Indexed keywords

CAPECITABINE; DOXORUBICIN;

AGED; ALOPECIA; ARTICLE; BREAST METASTASIS; CANCER GROWTH; CANCER RESEARCH; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; STOMATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY;

CAPECITABINE; ELDERLY; GERIATRIC; METASTATIC BREAST CANCER; PEGYLATED LIPOSOMAL DOXORUBICIN; PHASE III;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; NETHERLANDS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84896824306     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt588     Document Type: Article

References (18)

1. Cardoso F, Costa A, Norton L et al. 1st International consensus guidelines for advanced breast cancer. Breast 2012; 21: 242-252.
2. Debled M, Bellera C, Donamaria C et al. Chemotherapy treatment for older women with metastatic breast cancer: what is the evidence? Cancer Treat Rev 2011; 37: 590-598.
3. O'Shaughnessy JA, Blum J, Moiseyenko J et al. Randomized, open label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247-1254.
4. Feher O, Vodvarka P, Jassem J et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005; 6: 899-908.
5. Hamberg P, Verweij J, Seyanaeve C. Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur J Cancer 2007; 43: 1514-1528.
6. Biganzoli L, Wildiers H, Oakman C et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 2012; 13: e148-e160.
7. Green H, Stal O, Bachmeier K et al. Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified. Cancer Lett 2011; 27: 145-153.
8. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155-2161.
9. Hamaker ME, Seynaeve C, Wymenga ANM et al. Baseline comprehensive geriatric assessment is associated with toxicity ad survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch Breast Cancer Trialists' Group. Breast 2014; 23: 81-87.
10. Jager E, Al-Batran S, Saupe S et al. A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine for metastatic breast cancer. J Clin Oncol 2010; 28: 15s (supll; abstr 1022).
11. Kotsori AA, Noble JL, Ashley S et al. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment? Breast 2010; 19: 377-381.
12. Biganzoli L, Coleman R, Minisini A et al. A joined analysis of two European Organisation for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer. Crit Rec Oncol Hematol 2007; 61: 84-89.
13. Freyer G, Braud A-C, Chaibi P et al. Dealing with metastatic breast cancer in elderly women: results from a French study on a large cohort carried out by the 'Observatory on Elderly Patients'. Ann Oncol 2006; 17: 211-216.
14. Gerritse FL, Meulenbeld HJ, Roodhart JML et al. Analysis of docetaxel therapy in elderly (70 years old) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49: 3176-3183.
15. Hamaker ME, Seynaeve C, Wymenga ANM et al. Slow accrual of elderly patients with metastatic breast cancer in the Dutch multicentre OMEGA study. Breast 2013; 22: 556-559.
16. Crivellari D, Gray KP, Dellapasqua S et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast 2013; 22: 130-137.
17. Leonard R, Ballinger R, Cameron D et al. Adjuvant chemotherapy in older women (ACTION) study: what did we learn from the pilot phase? Br J Cancer 2011; 25: 1260-1266.
18. Wildiers H, Mauer M, Pallis A et al. End point and trial design in geriatric oncology research: a joint European Organisation for Research and Treatment of Cancer-alliance for clinical trials in oncology-International Society of Geriatric Oncology position article. J Clin Oncol 2013; 31: 3711-3718.